Healthcare / BiotechnologyStuttgart
$0.18
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-57.1M · quality 68.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
24/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$299M
P/E
N/A
•EV/EBITDA
N/A
•ROE
99.8%
↑Gross Margin
N/A
•Debt/Equity
-1.08
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.77x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-60.2M · FCF $-46.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Net Income | $-60.2M | $-60.2M | $-83.8M | $-62.6M | $-105.0M |
| EBITDA | $-49.7M | $-49.7M | $-74.0M | $-55.6M | $-97.5M |
| EPS | -0.04 | -0.04 | -0.07 | -0.06 | -0.10 |
| Balance Sheet | |||||
| Debt/Equity | -1.08 | -1.08 | -0.71 | -0.69 | -0.20 |
| Current Ratio | 0.07 | 0.07 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-46.3M | $-46.3M | $-58.0M | $-57.1M | $-55.7M |
| Returns | |||||
| ROE | 99.8% | 99.8% | 88.7% | 95.2% | 82.0% |
| Growth & Yield | |||||
| EPS Growth | 42.9% | 42.9% | -16.7% | 40.0% | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-27.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.07 → -0.04
Residual
-27.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.